<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04838808</url>
  </required_header>
  <id_info>
    <org_study_id>Pro00105055</org_study_id>
    <nct_id>NCT04838808</nct_id>
  </id_info>
  <brief_title>Rivaroxaban in Type 2 Myocardial Infarctions</brief_title>
  <acronym>R2MI</acronym>
  <official_title>Rivaroxaban in Type 2 Myocardial Infarctions: A Feasibility, Placebo-controlled, Double-blinded, Randomized Controlled Trial</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Alberta</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University of Alberta</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      This trial is the pilot phase of a randomized controlled trial to test the feasibility of&#xD;
      recruiting patients with a type 2 myocardial infarction and randomizing them to low-dose&#xD;
      rivaroxaban to reduce the risk of major cardiovascular events.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This trial is an investigator-initiated prospective, single-center, placebo-controlled,&#xD;
      double blinded, pilot randomized controlled trial of low-dose rivaroxaban (2.5mg oral twice&#xD;
      daily) for 90-days following a type 2 myocardial infarction. The primary feasibility outcome&#xD;
      is time to recruitment of 100 participants, stratified by sex.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">April 5, 2021</start_date>
  <completion_date type="Anticipated">December 31, 2021</completion_date>
  <primary_completion_date type="Anticipated">December 31, 2021</primary_completion_date>
  <phase>Phase 2/Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Feasibility outcome</measure>
    <time_frame>Through study completion, estimated at 1-year</time_frame>
    <description>Time to recruitment of 100 participants, stratified by sex.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Number of participants who experience a composite of death, stroke or myocardial infarction</measure>
    <time_frame>90-days</time_frame>
    <description>Composite of death, stroke or myocardial infarction</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of participants who experience major bleeding</measure>
    <time_frame>90-days</time_frame>
    <description>Major bleeding as per the International Society on Thrombosis and Haemostasis (ISTH) Fatal bleeding, symptomatic bleeding requiring presentation to an acute care facility or bleeding resulting in transfusion.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">100</enrollment>
  <condition>Type II Myocardial Infarction</condition>
  <arm_group>
    <arm_group_label>Rivaroxaban</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Rivaroxaban 2.5mg oral twice daily for 90-days</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Oral placebo tablet twice daily for 90-days</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Rivaroxaban 2.5 MG [Xarelto]</intervention_name>
    <description>Rivaroxaban 2.5mg twice daily for 90-days</description>
    <arm_group_label>Rivaroxaban</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Placebo tablet twice daily for 90-days</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Participant age â‰¥ 65years or &gt;45 years and an additional risk factor (smoking,&#xD;
             diabetes mellitus, hypertension, dyslipidemia or known atherosclerotic disease)&#xD;
&#xD;
          2. Rise in troponin level, with one troponin value above the 99th percentile of the upper&#xD;
             limit of normal deemed to be due to a type 2 myocardial infarction by the attending&#xD;
             team within the past 30 days&#xD;
&#xD;
          3. Alive at the time of hospital discharge&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Current use of anticoagulation&#xD;
&#xD;
          2. Current use of dual antiplatelet therapy&#xD;
&#xD;
          3. Advanced kidney disease (eGFR &lt;15ml/min)&#xD;
&#xD;
          4. Previous hemorrhagic stroke at any time or embolic stroke within the past year&#xD;
&#xD;
          5. Previous life-threatening bleeding event&#xD;
&#xD;
          6. Life expectancy less than one year&#xD;
&#xD;
          7. Anticoagulation recommended conditions - atrial fibrillation, pulmonary embolism, deep&#xD;
             vein thrombosis, mechanical heart valves, rheumatic mitral valve disease, left&#xD;
             ventricular thrombosis&#xD;
&#xD;
          8. Surgery in the previous 30 days&#xD;
&#xD;
          9. Inability to provide informed consent in English&#xD;
&#xD;
         10. Pregnancy, breastfeeding or child bearing potential&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>45 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Michelle Graham, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Alberta</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Michelle Graham, MD</last_name>
    <phone>780-407-1590</phone>
    <email>mmg2@ualberta.ca</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Pishoy Gouda, MD</last_name>
    <phone>780-660-4791</phone>
    <email>gouda@ualebrta.ca</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>University of Alberta</name>
      <address>
        <city>Edmonton</city>
        <state>Alberta</state>
        <zip>T6W 1T7</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Pishoy Gouda, MD</last_name>
      <phone>7806604791</phone>
      <email>gouda@ualberta.ca</email>
    </contact>
  </location>
  <location_countries>
    <country>Canada</country>
  </location_countries>
  <verification_date>March 2021</verification_date>
  <study_first_submitted>March 11, 2021</study_first_submitted>
  <study_first_submitted_qc>April 6, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">April 9, 2021</study_first_posted>
  <last_update_submitted>April 6, 2021</last_update_submitted>
  <last_update_submitted_qc>April 6, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">April 9, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>myocardial injury</keyword>
  <keyword>Type II myocardial infarction</keyword>
  <keyword>Anticoagulation</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Myocardial Infarction</mesh_term>
    <mesh_term>Infarction</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Rivaroxaban</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

